• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

July 21, 2022

Study: Gabapentin-Related Overdose Deaths Increasing, Associated with Opioid Use

Author(s):

Lindsey Mulrooney

The increase in gabapentin-related overdose deaths follows a rising trend in overall overdose deaths during the COVID-19 pandemic.

Gabapentin detection and involvement in overdose deaths increased during 2019 and 2020, according to a study published in the CDC’s Morbidity and Mortality Weekly Report. Gabapentin, an anticonvulsant medication and the seventh most commonly prescribed medication in the United States, can be used to potentiate illicit opioids.

“Although gabapentin is generally considered safe and is infrequently associated with overdose on its own, when used with other central nervous system depressants such as opioids, there is risk for respiratory depression, potentially resulting in death,” the authors wrote.

Researchers analyzed data from the State Unintentional Drug Overdose Reporting System (SUDORS) in 23 states and the District of Columbia to assess quarterly trends in gabapentin-involved overdose deaths of unintentional or undetermined intent during 2019 to 2020.

SUDORS requires jurisdictions to abstract data from death certificates and medical examiner or coroner reports, including postmortem toxicology reports. Postmortem toxicology reports identify detected drugs and those involved, meaning those determined to be the cause of death.

Of 62,652 overdose deaths occurring between 2019 and 2020 recorded in SUDORS, 58,362 deaths had documented toxicology results. Among these, 5687 (9.7%) had gabapentin detected on postmortem toxicology.

Gabapentin-involved deaths occurred in 2975 of 5687 decedents (52.3%) with a positive gabapentin test result. Most gabapentin-involved overdose deaths, 83.2%, occurred among non-Hispanic White persons. More than half of gabapentin-involved deaths, 52.2%, occurred among persons aged 35 to 54 years. Gabapentin-involved overdose deaths occurred with nearly equal frequency among men and women.

According to the report, the number of deaths reported with gabapentin detected approximately doubled during the second quarter of 2020 compared with the first quarter of 2019. A total of 801 deaths with gabapentin detected occurred during the fourth quarter of 2020.

Among deaths in which gabapentin was detected, nearly half, 49.4%, were gabapentin-involved during the first quarter of 2019. This percentage increased to 55.1% during the fourth quarter of 2020.

The percentage of opioid-involved deaths with gabapentin detected remained consistently high ranging from 85% to 90%, according to the report.

Illicit opioid-involved deaths accounted for 56.8% of overdose deaths with gabapentin detected in the first quarter of 2019 and 69.2% in the last quarter of 2020. The authors suggest that this increase was largely driven by illicitly manufactured fentanyl and fentanyl analogs.

The percentage of deaths with gabapentin detected that involved a prescription opioid declined from 41.9% in the first quarter of 2019 to 33% during the last quarter of 2020. The percentage of deaths with gabapentin detected that involved a stimulant was low and generally stable, ranging from 6% to 9%.

Nearly 90% of drug overdose deaths in which gabapentin was detected also involved an opioid.

Generally, gabapentin detection and involvement in fatal drug overdoses increased during 2019 to 2020. According to the report, this follows a rising trend in overall overdose deaths during the COVID-19 pandemic. The authors suggest that overall increases were largely driven by increases in synthetic opioids and likely exacerbated by the social and economic consequences of the pandemic.

They note that gabapentin testing is recommended as part of comprehensive postmortem toxicology testing protocols for postmortem toxicology testing protocols for drug overdose death investigations in the United States. However, as gabapentin is not included in the list of substances recommended in an adequate analyte panel and is not uniformly included on death certificates by some certifiers, deaths involving gabapentin or with gabapentin detected are likely underestimated.

They suggest including routine gabapentin testing as a part of comprehensive postmortem toxicology testing protocols for drug overdose death investigations to further elucidate the role of gabapentin in drug overdose deaths.

The finding that gabapentin detection and involvement in overdose deaths increased during 2019 to 2020 suggests the dangers of polysubstance use, particularly co-use of gabapentin and illicit opioids. The authors encourage educating persons who use illicit opioids with gabapentin about the increased risk for respiratory depression and death.

Reference

Mattson CL, Chowdhury F, Gilson TP. Trends in Gabapentin Detection and Involvement in Drug Overdose Deaths—23 States and the District of Columbia, 2019-2020. CDC MMWR. 2022;71(19). https://www.cdc.gov/mmwr/volumes/71/wr/mm7119a3.htm?s_cid=mm7119a3_w#contribAff. Published May 13, 2022. Accessed July 18, 2022.

Related Videos
Happy elderly patient with medical health checkup with cardiologist or geriatric doctor. Senior old aging woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Related Content
Advertisement
Red blood cells | Image Credit: © fotogurmespb - stock.adobe.com
May 15th 2025

Interferon Lowers Myelofibrosis Risk in Young Patients With Polycythemia Vera, Essential Thrombocytopenia

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Microscopic cellular structure of chronic lymphocytic leukemia | Image Credit: ©AI Photo Stock - stock.adobe.com
May 15th 2025

Real-World Study Shows Comparable Survival Outcomes With First-Line Ibrutinib in High-Risk and Non-High-Risk CLL/SLL

Alexandra Gerlach, Associate Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
Human brain digital illustration. Electrical activity, flashes and lightning on a blue background - Image credit: Siarhei | stock.adobe.com
May 15th 2025

FDA Grants Orphan Drug Designation to Oligonucleotide Therapeutic for Spinocerebellar Ataxia

Kennedy Ferruggia, Assistant Editor
Psilocybin -- Image credit: TaylerDerden | stock.adobe.com
May 15th 2025

The Promise of Psilocybin-Assisted Therapy for Opioid Use Disorder

Craig Kimble, PharmD, MBA, MS, BCACP, TTS Alberto Coustasse, DrPH, MD, MBA, MPH
Related Content
Advertisement
Red blood cells | Image Credit: © fotogurmespb - stock.adobe.com
May 15th 2025

Interferon Lowers Myelofibrosis Risk in Young Patients With Polycythemia Vera, Essential Thrombocytopenia

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Microscopic cellular structure of chronic lymphocytic leukemia | Image Credit: ©AI Photo Stock - stock.adobe.com
May 15th 2025

Real-World Study Shows Comparable Survival Outcomes With First-Line Ibrutinib in High-Risk and Non-High-Risk CLL/SLL

Alexandra Gerlach, Associate Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
Human brain digital illustration. Electrical activity, flashes and lightning on a blue background - Image credit: Siarhei | stock.adobe.com
May 15th 2025

FDA Grants Orphan Drug Designation to Oligonucleotide Therapeutic for Spinocerebellar Ataxia

Kennedy Ferruggia, Assistant Editor
Psilocybin -- Image credit: TaylerDerden | stock.adobe.com
May 15th 2025

The Promise of Psilocybin-Assisted Therapy for Opioid Use Disorder

Craig Kimble, PharmD, MBA, MS, BCACP, TTS Alberto Coustasse, DrPH, MD, MBA, MPH
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.